Advertisement

Topics

Fosun Pharma Pays $36 Million to Acquire GSK Suzhou Manufacturing Facility

02:50 EDT 10 Jul 2019 | ChinaBio Today

Shanghai Fosun Pharma paid $36 million to buy an older GlaxoSmithKline drug making facility in Suzhou, along with non-exclusive rights to manufacture lamivudine, a GSK treatment for hepatitis B/HIV. Last week, GSK officially opened a new $95 million Singapore facility that uses an enzyme-based continuous manufacturing process. The process is less expensive and more friendly to the environment than traditional chemical synthesis. Initially, GSK's new facility will produce Daprodustat, an oral treatment for anemia associated with chronic kidney disease. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (NYSE: GSK)

Share this with colleagues:

Original Article: Fosun Pharma Pays $36 Million to Acquire GSK Suzhou Manufacturing Facility

NEXT ARTICLE

More From BioPortfolio on "Fosun Pharma Pays $36 Million to Acquire GSK Suzhou Manufacturing Facility"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...